News
04-04-2011, 10:40 PM
Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.
More... (http://www.news-medical.net/news/20110405/Lilly-presents-results-of-JAK2-Hedgehog-inhibitor-preclinical-cancer-studies-at-102nd-AACR.aspx)
More... (http://www.news-medical.net/news/20110405/Lilly-presents-results-of-JAK2-Hedgehog-inhibitor-preclinical-cancer-studies-at-102nd-AACR.aspx)